Stock DZ
11.01.2018 kl 10:26

Today’s share price is in no way representative of the 20 dec press release, considering the increased LOA. Something I’m not concern about since I’m here for long term.

In my modest expectation and based on yesterday presentation I’m almost convinced that FimaVacc will be qualified as a commercial product well before Fimachem. As outlicensing contracts could be raining down well before end of 2018. The surprising thing is that Fimavac potential or even clinical trial progress is not even reflected in the today’s-price.

Just remember who came out as winners from the gold rush era in the US. It was the mining tools retailers.

FirmaVacc is not a drug but a tool to achieve better vaccine response “in simple words”